ATH434
Multiple System Atrophy (MSA)
Key Facts
About Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases. Its core strategy leverages a proprietary platform of metal protein attenuating compounds (MPACs) to inhibit the aggregation of pathological proteins like alpha-synuclein. The company's lead asset, ATH434, is in Phase 2 clinical trials for Multiple System Atrophy (MSA) and Parkinson's disease, targeting a significant unmet medical need. As a publicly listed entity on the ASX, Alterity is advancing its pipeline through focused clinical execution and strategic capital management.
View full company profileAbout Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases. Its core strategy leverages a proprietary platform of metal protein attenuating compounds (MPACs) to inhibit the aggregation of pathological proteins like alpha-synuclein. The company's lead asset, ATH434, is in Phase 2 clinical trials for Multiple System Atrophy (MSA) and Parkinson's disease, targeting a significant unmet medical need. As a publicly listed entity on the ASX, Alterity is advancing its pipeline through focused clinical execution and strategic capital management.
View full company profile